JS
Jean‐Marc Schwarz

Publications (6)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Article scientifique · 2023
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Article scientifique · 2023
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
Article scientifique · 2023
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
Article scientifique · 2023
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Article scientifique · 2023
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
Article scientifique · 2023

Domaines principaux

Sciences de la santé6

Statistiques

Consultations3
Téléchargements0